Latest & greatest articles for irritable bowel syndrome

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for irritable bowel syndrome

141. Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis

, Dulai G S. Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis. Gastroenterology 2004; 126(7): 1721-1732 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Celiac Disease /diagnosis /economics /epidemiology /prevention & Cost-Benefit Analysis; Diarrhea /diagnosis /economics; Diet; Glutens; Humans; Irritable Bowel Syndrome /diagnosis /economics /epidemiology /prevention & Mass Screening /economics; Prevalence; Sensitivity (...) Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis Spiegel B M R, DeRosa V P, Gralnek I M, Wang V, Dulai G S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion

2004 NHS Economic Evaluation Database.

142. Psychological treatments for irritable bowel syndrome: a systematic review and meta-analysis

Psychological treatments for irritable bowel syndrome: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.

143. A systematic review of alternative therapies in the irritable bowel syndrome

implications for practice. Research: The authors stated that well-designed trials are required in this area. Bibliographic details Spanier J A, Howden C W, Jones M P. A systematic review of alternative therapies in the irritable bowel syndrome. Archives of Internal Medicine 2003; 163(3): 265-274 PubMedID Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Behavior Therapy; Colonic Diseases, Functional /diet therapy /etiology /microbiology /psychology /therapy; Combined Modality Therapy (...) A systematic review of alternative therapies in the irritable bowel syndrome A systematic review of alternative therapies in the irritable bowel syndrome A systematic review of alternative therapies in the irritable bowel syndrome Spanier J A, Howden C W, Jones M P CRD summary This review concluded that there is no strong evidence for the effectiveness of alternative therapies in the treatment of irritable bowel syndrome. This was a poorly conducted review and it is unlikely that the findings

2003 DARE.

144. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials Cremonini F, Delgado-Aros S, Camilleri M CRD summary This review analysed six trials on the effects of alosetron in irritable bowel syndrome (IBS). The authors concluded that alosetron can improve (...) symptoms or decrease pain in female IBS patients without constipation. However, they also concluded that alosetron can have adverse effects, particularly constipation. The effects in men are unclear. These conclusions are appropriate given the evidence available. Authors' objectives To determine the effect of alosetron therapy on adequate relief of pain or global improvement of symptoms in patients with irritable bowel syndrome (IBS). Searching MEDLINE (from 1966 to 2002) and EMBASE (from 1988 to 2002

2003 DARE.

145. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome

The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 NHS Economic Evaluation Database.

146. Irritable bowel syndrome: a little understood organic bowel disease? (Abstract)

Irritable bowel syndrome: a little understood organic bowel disease? Irritable bowel syndrome affects 10% of adults with an unexplained female predominance. Although only a few people see their family doctor, the disease causes reduced quality of life and represents a multi-billion pound health-care problem. The disorder clusters in families, which is possibly because of intra-familial learning and a genetic predisposition. Visceral hypersensitivity is a key feature in most patients. Results (...) of imaging studies of regional cerebral blood flow during rectal distension suggest underlying disturbances of central processing of afferent signals, though this is not unique to the disorder, since it is seen in other chronic pain syndromes. Environmental factors that are strongly implicated in at least some patients include gastrointestinal infection and inflammation and chronic stress. Diagnosis is based on positive symptoms and absence of any alarm indicators. Treatment remains unsatisfactory

2002 Lancet

147. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review

The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2002 DARE.

148. Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. (Abstract)

Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. Irritable bowel syndrome has a high prevalence. Consensus diagnostic criteria (ROME II) based on symptoms have been established to aid diagnosis. Although coeliac disease can be misdiagnosed as irritable bowel syndrome, no prospective study has been published in which patients with this disorder are investigated for coeliac disease. We (...) aimed to assess the association of coeliac disease with irritable bowel syndrome in patients fulfilling ROME II criteria.We undertook a case-control study at a university hospital. 300 consecutive new patients who fulfilled Rome II criteria for irritable bowel syndrome, and 300 healthy controls (age and sex matched) were investigated for coeliac disease by analysis of serum IgA antigliadin, IgG antigliadin, and endomysial antibodies (EMA). Patients and controls with positive antibody results were

2001 Lancet

149. Treatment of irritable bowel syndrome: a review of randomised controlled trials

Treatment of irritable bowel syndrome: a review of randomised controlled trials Treatment of irritable bowel syndrome: a review of randomised controlled trials Treatment of irritable bowel syndrome: a review of randomised controlled trials Akehurst R, Kaltenthaler E Authors' objectives To review and assess published randomised controlled trials (RCTs) examining the clinical effectiveness of interventions for irritable bowel syndrome (IBS) treatments. Searching The Cochrane Library, DARE (...) of this review. Research: The authors state that 'it is essential that RCTs are conducted of consistently identified patients with clearly defined outcome measures. These outcome measures should not only deal with symptom relief but also improvement in quality of life and associated measures such as time off work'. Bibliographic details Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001; 48(2): 272-282 PubMedID Original Paper URL Other

2001 DARE.

150. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome

and reduce pain in irritable bowel syndrome. Evid Based Med 2001;6:153. Indexing Status Subject indexing assigned by NLM MeSH Abdominal Pain /drug therapy /etiology; Adult; Colonic Diseases, Functional /drug therapy /pathology; Female; Humans; Male; Middle Aged; Odds Ratio; Parasympatholytics /pharmacology /therapeutic use; Placebos; Treatment Outcome AccessionNumber 12001000657 Date bibliographic record published 30/06/2002 Date abstract record published 30/06/2002 Record Status This is a critical (...) . The keywords used were 'colonic disease', 'functional', irritable bowel syndrome' and 'randomised trial'. Additional studies were obtained by examining general reviews, references from published RCTs, and Current Contents, and by contacting pharmaceutical companies. In addition, recent meta-analyses in the Journal of Hepatogastroenterology were also used. Only published articles were considered for the review. Study selection Study designs of evaluations included in the review Only double-blind, placebo

2001 DARE.

151. Cost-effectiveness of endoscopy in irritable bowel syndrome

be reserved for patients in whom high diagnostic certainty is deemed necessary. Source of funding None stated. Bibliographic details Suleiman S, Sonnenberg A. Cost-effectiveness of endoscopy in irritable bowel syndrome. Archives of Internal Medicine 2001; 161: 369-375 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Colonic Diseases, Functional /diagnosis /economics; Colonoscopy /economics; Cost-Benefit Analysis; Decision Trees; Humans; Predictive Value of Tests; Sigmoidoscopy /economics (...) Cost-effectiveness of endoscopy in irritable bowel syndrome Cost-effectiveness of endoscopy in irritable bowel syndrome Cost-effectiveness of endoscopy in irritable bowel syndrome Suleiman S, Sonnenberg A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study

2001 NHS Economic Evaluation Database.

152. Tegaserod (Zelmac) (irritable bowel syndrome)

Tegaserod (Zelmac) (irritable bowel syndrome) Tegaserod (Zelmac) (irritable bowel syndrome) Tegaserod (Zelmac) (irritable bowel syndrome) Stachnik J Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Stachnik J. Tegaserod (Zelmac) (irritable bowel syndrome) University HealthSystem Consortium (UHC). Drug Monograph. 2001 Authors' objectives The UHC Drug Monographs (...) advantages, and they address issues concerning therapeutic interchange. Each monograph includes comprehensive information from the primary literature and provides recommendations for appropriate use. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Colonic Diseases, Functional /drug therapy Language Published English Country of organisation United States Address for correspondence University HealthSystem Consortium, 2001 Spring Rd., Suite 700, Oak Brook, IL 60523 USA. Tel: 630-954

2001 Health Technology Assessment (HTA) Database.

153. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. (Abstract)

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Irritable bowel syndrome (IBS) is a common gastrointestinal disorder with symptoms of abdominal pain, discomfort, and altered bowel function. Antagonists of the type 3 serotonin receptor (5-HT3) have shown promising results in the relief of IBS-associated symptoms. We aimed to confirm these findings by doing a randomised, placebo-controlled trial.We studied 647 female IBS patients (...) with diarrhoea-predominant or alternating bowel patterns (diarrhoea and constipation). 324 patients were assigned 1 mg alosetron and 323 placebo orally twice daily for 12 weeks, followed by a 4-week post-treatment period. Adequate relief of abdominal pain and discomfort was the primary endpoint; secondary endpoints included improvements in urgency, stool frequency, and stool consistency. Analysis was by intention to treat.79 (24%) of patients in the alosetron group and 53 (16%) in the placebo group dropped

2000 Lancet Controlled trial quality: predicted high

154. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized controlled trials

pain and loperamide reduces diarrhoea in irritable bowel syndrome. Evid Based Med 2001;6:20-1. Indexing Status Subject indexing assigned by NLM MeSH Antidiarrheals /therapeutic use; Colonic Diseases, Functional /drug therapy; Evidence-Based Medicine; Gastrointestinal Agents /therapeutic use; Humans; Loperamide /therapeutic use; Outcome Assessment (Health Care); Parasympatholytics /therapeutic use; Psychotropic Drugs /therapeutic use; Randomized Controlled Trials as Topic AccessionNumber 12000008660 (...) in the English language were identified in the following: MEDLINE from 1966 to 1999; EMBASE from 1980 to 1999; PsycINFO from 1967 to 1999; the Cochrane Trials Register; and bibliographies from all retrieved publications. The MeSH term was 'colonic diseases, functional' and a keyword search for 'irritable', 'functional' or 'spastic' adjacent to 'bowel' or 'colon' was performed. The search was supplemented by various combinations of truncated keywords that described the type of publication such as 'random

2000 DARE.

155. Lotronex (TM): therapy for diarrhea predominant irritable bowel syndrome

Lotronex (TM): therapy for diarrhea predominant irritable bowel syndrome Lotronex (TM): therapy for diarrhea predominant irritable bowel syndrome Lotronex (TM): therapy for diarrhea predominant irritable bowel syndrome McGahan L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McGahan L. Lotronex (TM): therapy for diarrhea predominant (...) irritable bowel syndrome. Ottawa: Canadian Coordinating Office for Health Technology Assessment/Office Canadien de Coordination de l'Evaluation des Technologies de la Sante (CCOHTA) 2000: 4 Authors' objectives To summarise the available evidence on Lotronex (TM) for diarrhea predominant irritable bowel syndrome (IBS). Authors' conclusions Lotronex (TM) has been approved for marketing in the United States for the treatment of IBS in women whose predominant symptom is diarrhea. Lotronex (TM) has not yet

2000 Health Technology Assessment (HTA) Database.

156. Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. (Abstract)

Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. Irritable bowel syndrome (IBS) is a common functional bowel disorder for which there is no reliable medical treatment.To determine whether Chinese herbal medicine (CHM) is of any benefit in the treatment of IBS.Randomized, double-blind, placebo-controlled trial conducted during 1996 through 1997.Patients were recruited through 2 teaching hospitals and 5 private practices of gastroenterologists (...) , and herbalists were all blinded to treatment group.Change in total bowel symptom scale scores and global improvement assessed by patients and gastroenterologists and change in the degree of interference in life caused by IBS symptoms assessed by patients.Compared with patients in the placebo group, patients in the active treatment groups (standard and individualized CHM) had significant improvement in bowel symptom scores as rated by patients (P=.03) and by gastroenterologists (P=.001), and significant

1998 JAMA Controlled trial quality: predicted high

157. Abnormal colonic fermentation in irritable bowel syndrome. (Abstract)

Abnormal colonic fermentation in irritable bowel syndrome. The cause of irritable bowel syndrome (IBS) is unknown. It may follow gastroenteritis and be associated with an abnormal gut flora and with food intolerance. Our study was designed to assess whether these factors were associated with colonic malfermentation.We carried out a crossover controlled trial of a standard diet and an exclusion diet matched for macronutrients in six female IBS patients and six female controls. During the final

1998 Lancet Controlled trial quality: uncertain

158. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis

Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

1998 DARE.

159. Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials

Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials Talley N J, Owen B K, Boyce P, Paterson K Authors' objectives To determine whether psychological treatments are of value in irritable bowel syndrome (IBS). Searching The studies were identified by searching (...) issues in the future should lead to a better understanding of the place of psychological treatments in IBS. The authors provide a list of recommendations (Table 6), based on their results, to assist those who may wish to design future trials in this field. Bibliographic details Talley N J, Owen B K, Boyce P, Paterson K. Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials. American Journal of Gastroenterology 1996; 91(2): 277-286 PubMedID Indexing Status

1996 DARE.

160. Individual and group hypnotherapy in treatment of refractory irritable bowel syndrome. (Abstract)

Individual and group hypnotherapy in treatment of refractory irritable bowel syndrome. 33 patients with refractory irritable bowel syndrome were treated with four 40-minute sessions of hypnotherapy over 7 weeks. 20 improved, 11 of whom lost almost all their symptoms. Short-term improvement was maintained for 3 months without further formal treatment. Hypnotherapy in groups of up to 8 patients was as effective as individual therapy.

1989 Lancet Controlled trial quality: uncertain